Cancer risk assessment software firm CancerIQ is highlighting positive clinical results from research presented March 17 at the National Consortium of Breast Centers (NCBC) annual Interdisciplinary Breast Center meeting in Las Vegas.
In a study to assess a program for screening and identifying women at high risk for hereditary breast cancer, researchers from Riverside Healthcare of Kankakee, IL, compared results from a paper screening system between September 2016 and August 2017 with those from CancerIQ's Screening Toolkit between September 2017 and August 2018.
The research showed that CancerIQ's Screening Toolkit identified 2.5 times more women as having a high hereditary risk of breast cancer and doubled the number of women eligible for ongoing breast MRI surveillance compared with the paper system, the company said.
In other CancerIQ news, the company has formed news partnerships with Cordata Healthcare Innovations, MRS Systems, and PenRad Technologies.
